nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—forelimb—Parkinson's disease	0.0603	0.226	CbGeAlD
Pimecrolimus—MTOR—hindbrain—Parkinson's disease	0.0247	0.0925	CbGeAlD
Pimecrolimus—MTOR—embryo—Parkinson's disease	0.0155	0.0579	CbGeAlD
Pimecrolimus—MTOR—brainstem—Parkinson's disease	0.0142	0.053	CbGeAlD
Pimecrolimus—MTOR—forebrain—Parkinson's disease	0.0137	0.0512	CbGeAlD
Pimecrolimus—FKBP1A—forebrain—Parkinson's disease	0.0123	0.046	CbGeAlD
Pimecrolimus—MTOR—cardiovascular system—Parkinson's disease	0.0116	0.0433	CbGeAlD
Pimecrolimus—FKBP1A—cardiovascular system—Parkinson's disease	0.0104	0.0389	CbGeAlD
Pimecrolimus—FKBP1A—medulla oblongata—Parkinson's disease	0.00888	0.0333	CbGeAlD
Pimecrolimus—MTOR—spinal cord—Parkinson's disease	0.00881	0.033	CbGeAlD
Pimecrolimus—FKBP1A—midbrain—Parkinson's disease	0.00812	0.0304	CbGeAlD
Pimecrolimus—FKBP1A—spinal cord—Parkinson's disease	0.00792	0.0297	CbGeAlD
Pimecrolimus—MTOR—head—Parkinson's disease	0.00783	0.0293	CbGeAlD
Pimecrolimus—MTOR—nervous system—Parkinson's disease	0.00742	0.0278	CbGeAlD
Pimecrolimus—MTOR—central nervous system—Parkinson's disease	0.00714	0.0267	CbGeAlD
Pimecrolimus—FKBP1A—head—Parkinson's disease	0.00704	0.0264	CbGeAlD
Pimecrolimus—MTOR—cerebellum—Parkinson's disease	0.00698	0.0261	CbGeAlD
Pimecrolimus—FKBP1A—nervous system—Parkinson's disease	0.00667	0.025	CbGeAlD
Pimecrolimus—FKBP1A—central nervous system—Parkinson's disease	0.00643	0.0241	CbGeAlD
Pimecrolimus—FKBP1A—cerebellum—Parkinson's disease	0.00628	0.0235	CbGeAlD
Pimecrolimus—MTOR—brain—Parkinson's disease	0.00567	0.0212	CbGeAlD
Pimecrolimus—Temsirolimus—CYP2D6—Parkinson's disease	0.00522	0.337	CrCbGaD
Pimecrolimus—FKBP1A—brain—Parkinson's disease	0.0051	0.0191	CbGeAlD
Pimecrolimus—Temsirolimus—ABCB1—Parkinson's disease	0.00373	0.24	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—Parkinson's disease	0.00328	0.212	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—Parkinson's disease	0.00328	0.212	CrCbGaD
Pimecrolimus—CYP3A4—nervous system—Parkinson's disease	0.00218	0.00816	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—Parkinson's disease	0.0021	0.00786	CbGeAlD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL1B—Parkinson's disease	0.00118	0.00164	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—MAPK8—Parkinson's disease	0.00117	0.00164	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—BDNF—Parkinson's disease	0.00117	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—INS—Parkinson's disease	0.00116	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—MAPK8—Parkinson's disease	0.00116	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—MAPK8—Parkinson's disease	0.00116	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF20—Parkinson's disease	0.00114	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—ABL1—Parkinson's disease	0.00114	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—INS—Parkinson's disease	0.00112	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ADORA2A—Parkinson's disease	0.00111	0.00154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TAF1—Parkinson's disease	0.0011	0.00154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FBP1—Parkinson's disease	0.0011	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—CASP3—Parkinson's disease	0.0011	0.00154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VPS35—Parkinson's disease	0.0011	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ADRBK1—Parkinson's disease	0.00109	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—ABL1—Parkinson's disease	0.00108	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—IGF1R—Parkinson's disease	0.00105	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NGF—Parkinson's disease	0.00104	0.00144	CbGpPWpGaD
Pimecrolimus—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	0.00101	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—MAPK8—Parkinson's disease	0.00101	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—INS—Parkinson's disease	0.00101	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—IL1B—Parkinson's disease	0.000985	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—HSPA8—Parkinson's disease	0.000976	0.00136	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tryptophan metabolism—CYP2E1—Parkinson's disease	0.000971	0.00135	CbGpPWpGaD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	0.000966	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—MAPK8—Parkinson's disease	0.000954	0.00133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	0.000937	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—INS—Parkinson's disease	0.000931	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—Parkinson's disease	0.000916	0.00128	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GPR37—Parkinson's disease	0.000908	0.00127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DGKQ—Parkinson's disease	0.000908	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—MAPK8—Parkinson's disease	0.000903	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—HSPA1A—Parkinson's disease	0.000888	0.00124	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—Parkinson's disease	0.000884	0.00123	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SNCA—Parkinson's disease	0.000881	0.00123	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RPL6—Parkinson's disease	0.000881	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—VPS35—Parkinson's disease	0.00088	0.00123	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	0.000859	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MAPK8—Parkinson's disease	0.000857	0.0012	CbGpPWpGaD
Pimecrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	0.000847	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CYCS—Parkinson's disease	0.000847	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ADRBK1—Parkinson's disease	0.000839	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—Parkinson's disease	0.000838	0.00117	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00083	0.00116	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	0.000827	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—MAPK8—Parkinson's disease	0.000825	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MCCC1—Parkinson's disease	0.000818	0.00114	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.000785	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NGF—Parkinson's disease	0.000778	0.00108	CbGpPWpGaD
Pimecrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.000775	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TALDO1—Parkinson's disease	0.000769	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—OMD—Parkinson's disease	0.000769	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—DCTN1—Parkinson's disease	0.000767	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—SOD1—Parkinson's disease	0.000765	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	0.00076	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—Parkinson's disease	0.000752	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—GSTP1—Parkinson's disease	0.000746	0.00104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RIT2—Parkinson's disease	0.000726	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PLA2G6—Parkinson's disease	0.00072	0.001	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—Parkinson's disease	0.000713	0.000995	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DRA—Parkinson's disease	0.000698	0.000973	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.000696	0.00097	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—MAPK8—Parkinson's disease	0.00069	0.000962	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—SOD2—Parkinson's disease	0.000689	0.00096	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GRK5—Parkinson's disease	0.000688	0.000959	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RPL23A—Parkinson's disease	0.000668	0.000931	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RPL14—Parkinson's disease	0.000668	0.000931	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—GPX1—Parkinson's disease	0.000657	0.000916	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—Parkinson's disease	0.000653	0.00091	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF20—Parkinson's disease	0.000652	0.000908	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.000637	0.000888	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PARK2—Parkinson's disease	0.000631	0.000879	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF20—Parkinson's disease	0.000626	0.000872	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF20—Parkinson's disease	0.000623	0.000868	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RPS8—Parkinson's disease	0.000623	0.000868	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TAF1—Parkinson's disease	0.00062	0.000864	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FBP1—Parkinson's disease	0.00062	0.000864	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GRM4—Parkinson's disease	0.000617	0.00086	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VPS35—Parkinson's disease	0.000616	0.000859	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	0.000601	0.000838	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NGF—Parkinson's disease	0.000598	0.000834	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PENK—Parkinson's disease	0.000585	0.000816	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAG—Parkinson's disease	0.000585	0.000816	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—CASP3—Parkinson's disease	0.000583	0.000813	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—Parkinson's disease	0.000561	0.000782	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	0.000558	0.000778	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	0.000551	0.000768	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—MAPK8—Parkinson's disease	0.000536	0.000747	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDYN—Parkinson's disease	0.000535	0.000746	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.000524	0.00073	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—Parkinson's disease	0.000522	0.000727	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GPR37—Parkinson's disease	0.000511	0.000712	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DGKQ—Parkinson's disease	0.000511	0.000712	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—Parkinson's disease	0.000507	0.000707	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GFAP—Parkinson's disease	0.000503	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—Parkinson's disease	0.000503	0.000701	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	0.000498	0.000694	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GRM5—Parkinson's disease	0.000498	0.000694	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL6—Parkinson's disease	0.000496	0.000691	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SNCA—Parkinson's disease	0.000496	0.000691	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—MAPK8—Parkinson's disease	0.000492	0.000687	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—Parkinson's disease	0.00049	0.000683	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—Parkinson's disease	0.00049	0.000683	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK8—Parkinson's disease	0.000488	0.00068	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ADRBK1—Parkinson's disease	0.000479	0.000667	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PPP1R1B—Parkinson's disease	0.000467	0.000651	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—DCTN1—Parkinson's disease	0.000466	0.000649	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ADRBK1—Parkinson's disease	0.000458	0.000638	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HSPA1A—Parkinson's disease	0.000454	0.000634	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK8—Parkinson's disease	0.000454	0.000633	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—Parkinson's disease	0.000441	0.000614	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF20—Parkinson's disease	0.000436	0.000608	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—Parkinson's disease	0.000434	0.000605	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRA—Parkinson's disease	0.000424	0.00059	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADORA2A—Parkinson's disease	0.000423	0.00059	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PLA2G6—Parkinson's disease	0.000419	0.000584	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—Parkinson's disease	0.00041	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RIT2—Parkinson's disease	0.000408	0.000569	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—Parkinson's disease	0.000407	0.000567	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INSR—Parkinson's disease	0.00039	0.000544	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ABL1—Parkinson's disease	0.00039	0.000544	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRK5—Parkinson's disease	0.000387	0.00054	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PARK2—Parkinson's disease	0.000383	0.000533	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF20—Parkinson's disease	0.000379	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL23A—Parkinson's disease	0.000376	0.000524	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL14—Parkinson's disease	0.000376	0.000524	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	0.00037	0.000516	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGB—Parkinson's disease	0.000369	0.000514	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR1A—Parkinson's disease	0.000367	0.000512	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.000365	0.000508	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TAC1—Parkinson's disease	0.000361	0.000504	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD1—Parkinson's disease	0.000354	0.000494	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPS8—Parkinson's disease	0.00035	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF20—Parkinson's disease	0.00035	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—Parkinson's disease	0.000348	0.000485	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRM4—Parkinson's disease	0.000347	0.000484	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD3—Parkinson's disease	0.000343	0.000479	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	0.000338	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CASP3—Parkinson's disease	0.000337	0.000469	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000334	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—Parkinson's disease	0.000333	0.000464	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK8—Parkinson's disease	0.00033	0.00046	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PENK—Parkinson's disease	0.000329	0.000459	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAG—Parkinson's disease	0.000329	0.000459	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—Parkinson's disease	0.000328	0.000457	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRBK1—Parkinson's disease	0.000321	0.000447	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—Parkinson's disease	0.000313	0.000436	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—Parkinson's disease	0.000311	0.000434	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR7—Parkinson's disease	0.00031	0.000433	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD2—Parkinson's disease	0.00031	0.000433	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—Parkinson's disease	0.00031	0.000432	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—Parkinson's disease	0.00031	0.000432	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK8—Parkinson's disease	0.000309	0.000431	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—Parkinson's disease	0.000308	0.00043	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDYN—Parkinson's disease	0.000301	0.00042	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—Parkinson's disease	0.00029	0.000404	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—Parkinson's disease	0.00029	0.000404	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	0.00029	0.000404	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—Parkinson's disease	0.000289	0.000402	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—Parkinson's disease	0.000287	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—Parkinson's disease	0.000285	0.000397	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—Parkinson's disease	0.000284	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GFAP—Parkinson's disease	0.000283	0.000394	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—COMT—Parkinson's disease	0.00028	0.000391	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRM5—Parkinson's disease	0.00028	0.00039	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	0.000279	0.000389	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ADRBK1—Parkinson's disease	0.000279	0.000389	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	0.000278	0.000388	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	0.000276	0.000385	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	0.000275	0.000384	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF2—Parkinson's disease	0.00026	0.000363	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ADRBK1—Parkinson's disease	0.000257	0.000359	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	0.000257	0.000358	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	0.000256	0.000357	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HSPA1A—Parkinson's disease	0.000256	0.000356	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	0.000253	0.000352	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1R—Parkinson's disease	0.000252	0.000351	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EDN1—Parkinson's disease	0.000249	0.000347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—INS—Parkinson's disease	0.000247	0.000344	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF20—Parkinson's disease	0.000245	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADORA2A—Parkinson's disease	0.000238	0.000332	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NGF—Parkinson's disease	0.000228	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ABL1—Parkinson's disease	0.000227	0.000317	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INSR—Parkinson's disease	0.00022	0.000306	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR2A—Parkinson's disease	0.000217	0.000303	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HGF—Parkinson's disease	0.000214	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—Parkinson's disease	0.000211	0.000294	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGB—Parkinson's disease	0.000208	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR1A—Parkinson's disease	0.000206	0.000288	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TAC1—Parkinson's disease	0.000203	0.000283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—Parkinson's disease	0.000202	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD1—Parkinson's disease	0.000199	0.000278	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—Parkinson's disease	0.000198	0.000275	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD3—Parkinson's disease	0.000193	0.000269	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ND3—Parkinson's disease	0.000182	0.000253	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MCCC1—Parkinson's disease	0.000182	0.000253	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRBK1—Parkinson's disease	0.00018	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK8—Parkinson's disease	0.000177	0.000246	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR7—Parkinson's disease	0.000175	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD2—Parkinson's disease	0.000175	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—Parkinson's disease	0.000174	0.000243	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INS—Parkinson's disease	0.000173	0.000241	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—OMD—Parkinson's disease	0.000171	0.000238	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TALDO1—Parkinson's disease	0.000171	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—Parkinson's disease	0.000162	0.000226	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	0.000162	0.000226	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCH1—Parkinson's disease	0.000155	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF2—Parkinson's disease	0.000146	0.000204	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—Parkinson's disease	0.000141	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—Parkinson's disease	0.00014	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—Parkinson's disease	0.000139	0.000193	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DBH—Parkinson's disease	0.000138	0.000192	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FBP1—Parkinson's disease	0.000138	0.000192	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GBA—Parkinson's disease	0.000138	0.000192	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—Parkinson's disease	0.000129	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGF—Parkinson's disease	0.000128	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR2A—Parkinson's disease	0.000122	0.00017	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK8—Parkinson's disease	0.000118	0.000165	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—Parkinson's disease	0.000114	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—Parkinson's disease	0.000113	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—Parkinson's disease	0.000112	0.000156	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—Parkinson's disease	0.000108	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK8—Parkinson's disease	0.000103	0.000143	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DDC—Parkinson's disease	0.000101	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—Parkinson's disease	9.71e-05	0.000135	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA4—Parkinson's disease	9.55e-05	0.000133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	8.6e-05	0.00012	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MAOB—Parkinson's disease	8.51e-05	0.000119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—Parkinson's disease	7.55e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—Parkinson's disease	7.23e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK8—Parkinson's disease	6.65e-05	9.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—Parkinson's disease	6.56e-05	9.15e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	6.32e-05	8.82e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CTGF—Parkinson's disease	6.21e-05	8.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—Parkinson's disease	6.06e-05	8.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	5.78e-05	8.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—Parkinson's disease	5.72e-05	7.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TH—Parkinson's disease	5.64e-05	7.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYCS—Parkinson's disease	5.41e-05	7.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COMT—Parkinson's disease	4.79e-05	6.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—Parkinson's disease	4.77e-05	6.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MAOA—Parkinson's disease	4.76e-05	6.63e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—Parkinson's disease	4.7e-05	6.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—Parkinson's disease	4.52e-05	6.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—Parkinson's disease	4.38e-05	6.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—Parkinson's disease	4.24e-05	5.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—Parkinson's disease	4.2e-05	5.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—Parkinson's disease	3.87e-05	5.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—Parkinson's disease	3.61e-05	5.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—Parkinson's disease	3.08e-05	4.3e-05	CbGpPWpGaD
